Sorafenib for Desmoid Tumors Ups Progression-Free Survival
Sorafenib prolongs progression-free survival among patients with desmoid tumors, according to a study published in the December 20 issue of the New England Journal of Medicine.
Bone and Connective Tissue Cancer
Nirogacestat Gets Fast-Tracked for the Treatment of Desmoid Tumors
The Company is planning a Phase 3 study (DeFi) sometime in the first half of 2019.
Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
The researchers found that median progression-free survival was 10.3 and 4.7 months in the elotuzumab and control groups, respectively, after a minimum follow-up period of 9.1 months.
New Formulation of Levoleucovorin Gets FDA Approval
Khapzory will be supplied in single-dose vials containing 175mg and 300mg of levoleucovorin lyophilized powder for reconstitution before intravenous administration.
Treatment for Rare Pediatric Cancer Granted Orphan Drug Designation
CLR 131 is an investigational radioiodinated Phospholipid Drug Conjugate (PDC) drug candidate that delivers cytotoxic radiation directly and selectively to malignant cells.
Adipocytes May Clear Daunorubicin, Contribute to Poorer Survival Outcomes
The researchers found that adipocytes absorbed and metabolized daunorubicin to daunorubicinol, which reduced its anti-leukemia effect. Daunorubicin conversion to daunorubicinol was confirmed in vivo in murine studies.
Massage Improves Pain, Lymphedema in Female CA Patients
The researchers found that all participants reported a positive experience with aromatherapy massage.
ANDA Accepted for Generic Doxil Injection
Merrimack announced that the FDA has accepted for review the ANDA for generic Doxorubicin Hydrochloride (HCI) Liposome Injection.
Lartruvo Approved for Soft Tissue Sarcoma
The Food and Drug Administration has granted accelerated approval to Lartruvo (olaratumab) injection with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS).
Antifungal-Chemotherapy Drug Interaction Update
The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.
